Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 1 of 1 for:    NCT01236391
Previous Study | Return to List | Next Study

Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL) (PCYC-1104-CA)

This study has been completed.
Janssen Pharmaceuticals
Information provided by (Responsible Party):
Pharmacyclics LLC. Identifier:
First received: October 18, 2010
Last updated: August 24, 2015
Last verified: August 2015
Results First Received: February 12, 2015  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Mantle Cell Lymphoma
Intervention: Drug: PCI-32765

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
One hundred fifteen subjects were enrolled and 111 subjects received at least 1 dose of ibrutinib and constitute the all treated population and the safety analysis set.

Reporting Groups
PCI-32765 Participants received 560 mg daily

Participant Flow:   Overall Study
STARTED   111 [1] 
COMPLETED   95 [2] 
[1] Participants who received study treatment
[2] Participants who were on treatment or discontinued treatment due to disease progression or death

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
One hundred fifteen subjects were enrolled and 111 subjects received at least 1 dose of ibrutinib and constitute the all treated population and the safety analysis set.

Reporting Groups
PCI-32765 PCI-32765: 560 mg daily

Baseline Measures
Overall Participants Analyzed 
[Units: Participants]
[Units: Participants]
<=18 years   0 
Between 18 and 65 years   41 
>=65 years   70 
[Units: Years]
Mean (Standard Deviation)
 67.1  (8.6) 
[Units: Participants]
Female   26 
Male   85 
Region of Enrollment 
[Units: Participants]
United States   78 
Poland   10 
Germany   3 
United Kingdom   20 

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percentage of Participants Achieving Response   [ Time Frame: The median follow-up time on study for all treated participants is 15.3 (range 1.9 - 22.3) months ]

2.  Secondary:   Number of Participants With Treatment Emergent Adverse Events (AEs)   [ Time Frame: From first dose of PCI-32765 to within 30 days of last dose for each participant or until study closure ]

3.  Secondary:   PCI-32765 and Its Metabolite (PCI-45227) AUC0-24h After Repeat Dosing of PCI-32765   [ Time Frame: Performed During the First Month of Receiving PCI-32765 ]

4.  Secondary:   Mean Change From Baseline to Cycle 5 in EORTC QLQ-C30 Global Health Status Score   [ Time Frame: From Baseline to Cycle 5 (Week 20) ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Dr. Darrin Beaupre
Organization: Pharmacyclics, Inc.
phone: 855-427-8846

Publications automatically indexed to this study by Identifier (NCT Number):

Responsible Party: Pharmacyclics LLC. Identifier: NCT01236391     History of Changes
Other Study ID Numbers: PCYC-1104-CA
PCI-32765 ( Other Identifier: Pharmacyclics )
Study First Received: October 18, 2010
Results First Received: February 12, 2015
Last Updated: August 24, 2015